Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...

Global markets have recently experienced volatility, with U.S. stocks ending the week lower amid tariff uncertainties and mixed economic data, such as unexpected job growth figures and fluctuating ...

Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.

Bulls and bears are in a lively debate between positive trends in economic and earnings growth versus persistent inflation ...

Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...